Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Merck's 3Q Revenues up 4% | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Merck’s 3Q Revenues up 4%

KEYTRUDA drives growth in the quarter with $7.4 billion in sales, helping to offset declines for Gardasil, Januvia and Lagevrio.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Merck
3Q Revenues: $16.7 billion (+4%)
3Q Earnings: $3.15 billion (-33%)
YTD Revenues: $48.5 billion (+7%)
YTD Earnings: $13.4 billion (earnings were $1.6 billion YTD23)
Comments: KEYTRUDA sales were up 17% to $7.4 billion in the quarter. Newly launched WINREVAIR to treat Pulmonary Arterial Hypertension had sales of $149 million. Gardasil sales were down 10% to $2.3 billion primarily due to lower demand in China, partially offset by higher sales in the U.S. Januvia sales were down 38% to $482 million, due to lower pricing in the U.S., as well as ongoing generic competition. Bridion sales were flat at $420 million. Covid-19 drug Lagevrio sales were down 36% to $383 million due to lower demand in Japan, partially offset by uptake from commercial launch in the U.S. Lynparza sales were up 13% to $337 million. Earnings in the quarter were impacted by the acquisition of Eyebiotech and a related development milestone.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters